Results 101 to 110 of about 38,476 (212)

Effectiveness of direct oral anticoagulants for all‐cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
This study shows that overweight and obese patients with atrial fibrillation experience improved outcomes when treated with DOACs compared with VKAs. Specifically, DOAC use was associated with lower risks of all‐cause mortality and cardiovascular events.
Danilo Menichelli, Gianluca Gazzaniga, Emilia Antonucci, Gualtiero Palareti, Daniela Poli, Pasquale Pignatelli, Daniele Pastori, the START2 Register Investigators, Benilde Cosmi, Daniela Poli, Elena Lotti, Martina Berteotti, Walter Ageno, Giovanna Colombo, Salvatore Bradamante, Eugenio Bucherini, Monica Vastola, Paola Casasco, Antonio Chistolini, Alessandra Serrao, Luciano Crippa Ambulatorio Emostasi, Raimondo De Cristofaro, Erica De Candia, Valeria De Micheli, Marcello Di Nisio, Anna Falanga, Teresa Lerede, Elvira Grandone, Donatella Colaizzo, Antonio Insana, Nicola Lucio Liberato, Domenico Lione, Rosa Maria Lombardi, Giacomo Lucarelli, Giuseppe Malcangi, Catello Mangione, Giuliana Martini Centro Emostasi, Marco Marzolo, Giovanni Nante, Vincenzo Oriana, Paolo Pedico, Simona Pedrini, Vittorio Pengo, Antonietta Piana, Francesco Cibecchini, Simona Pezzella, Pasquale Pignatelli, Daniele Pastori, Vincenza Rossi, Lucia Ruocco, Paolo Chiarugi, Serena Rupoli, Domizio Serra, Carmine Spataro, Margherita Reduzzi, Sophie Testa, Oriana Paoletti, Vincenzo Toschi, Claudio Vasselli   +58 more
wiley   +1 more source

Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management [PDF]

, 2017
Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation ...
Cheung, KS, Leung, WK
core   +1 more source

Supratherapeutic dabigatran: a cause of life‐threatening haemorrhage* [PDF]

, 2023
Mairead M. Hennessy, B. Reidy, Fionnuala Ní Áinle, John B. Conneely, Cian McDermott, P. Ó. Scanaill   +5 more
openalex   +1 more source

Catheter Ablation Is Associated With a Decrease in Major Adverse Cardiovascular Events and All‐Cause Mortality in Patients With Atrial Fibrillation and Obstructive Sleep Apnea

Journal of Cardiovascular Electrophysiology, Volume 37, Issue 1, Page 36-45, January 2026.
ABSTRACT Introduction Obstructive sleep apnea (OSA) is a common risk factor for the development and progression of atrial fibrillation (AF). Whether catheter ablation for AF management in patients with coexisting OSA yields survival benefit remains unclear.
Ghassan Bidaoui, Christian Massad, Joe Abi‐Rached, Ahmed Abdelmaksoud, Eman Toraih, Michel Abou‐Khalil, Mayana Bsoul, Montaser Atasi, Amitabh Pandey, Nassir Marrouche, and other members of the TRIAD Team, Yara Menassa, Han Feng, Swati Rao, Chanho Lim, Ala' Assaf, Hadi Younes   +16 more
wiley   +1 more source

Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation

Journal of the Formosan Medical Association, 2019
Background/purpose: Dabigatran is effective in preventing ischemic stroke and systemic embolism in patients with atrial fibrillation. Although the therapeutic window for dabigatran is wide, its pharmacokinetic properties can differ between specific ...
Shin-Yi Lin, Sung-Chun Tang, Ching-Hua Kuo, Li-Kai Tsai, Shin-Joe Yeh, Li-Jiuan Shen, Jiann-Shing Jeng   +6 more
doaj   +1 more source

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation -a look beyond the excellent results [PDF]

, 2012
In this overview we address the three phase III studies that compared new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the setting of stroke prevention in atrial fibrillation.
Crippa, L, Falanga, A, Finazzi, G, Manotti, C., Marongiu, F, Moia, M, Palareti, G, Pengo, V, Poli, D, Policarpo, D, SIRAGUSA, Sergio, TESTA, Silvia, Tiraferri, E, Tosetto, A, Tripodi, A   +14 more
core   +1 more source

Anticoagulant or Antithrombotic Therapy After Early Neurological Deterioration in Patients With Branch Atheromatous Disease Receiving Dual Antiplatelet Therapy

International Journal of Clinical Practice, Volume 2026, Issue 1, 2026.
Objective We evaluated the effectiveness and safety of adding tirofiban or argatroban after early neurological deterioration (END) in patients with branch atheromatous disease (BAD) receiving dual antiplatelet therapy and compared the outcomes with those of patients who continued dual antiplatelet therapy alone. Methods This retrospective study focused
Xuemin Zhong, Juan Yang, Ronghua Xu, Jian Wang, Nikhat Kaura   +4 more
wiley   +1 more source

UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.

PLoS ONE, 2015
IntroductionThe fast, precise, and accurate measurement of the new generation of oral anticoagulants such as dabigatran and rivaroxaban in patients' plasma my provide important information in different clinical circumstances such as in the case of ...
Joachim Kuhn, Tatjana Gripp, Tobias Flieder, Marcus Dittrich, Doris Hendig, Jessica Busse, Cornelius Knabbe, Ingvild Birschmann   +7 more
doaj   +1 more source

Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting [PDF]

, 2016
BACKGROUND: Thromboprophylaxis is recommended for patients undergoing total hip or total knee replacement (THR, TKR). An international, open-label, prospective, observational, single-arm study in a routine clinical setting was performed to assess the ...
Brueckmann, Martina, Clemens, Andreas, Feuring, Martin, Frostick, Simon, Kleine, Eva, Rosencher, Nadia, Samama, Charles M   +6 more
core   +1 more source

Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study

Drugs - Real World Outcomes, 2019
Introduction The new user cohort design is widely used to assess the effects of a new drug, such as dabigatran, but inherently excludes some users due to prior use of the comparator drug, for example warfarin.
Hui-Min Diana Lin, Chao-Lun Lai, Yaa-Hui Dong, Yu-Kang Tu, K. Arnold Chan, Samy Suissa   +5 more
doaj   +1 more source